Circulating miRNA-141 as a non-invasive biomarker for prostate cancer detection and prognosis
10.3969/j.issn.1000-4718.2014.10.028
- VernacularTitle:循环 miRNA-141对前列腺癌的诊断和预后价值研究
- Author:
Yufeng LIAO
;
Jinhua DAI
;
Qifeng MAO
;
Zhankun ZHU
;
Guangcheng JIA
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Benign prostate hyperplasia;
miR-141
- From:
Chinese Journal of Pathophysiology
2014;(10):1887-1890
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To analyze circulating miR-141 in the serum as a non-invasive biomarker in the patients with prostate cancer ( PCa) and benign prostate hyperplasia ( BPH) , and healthy individuals.METHODS: A total of 75 pa-tients with PCa, 52 with BPH and 40 healthy individuals were enrolled into this study.Total RNA was isolated from the se-rum samples and the circulating levels of miR-141 were determined using quantitative real-time polymerase chain reaction. RESULTS:The serum levels of miR-141 were significantly higher in the patients with PCa compared to the patients with BPH and the healthy controls (P<0.01).The level of miR-141 in PCa group obviously differed from that in BPH group and healthy control group with high diagnosis performance, with areas under the curve of 0.785 and 0.801, respectively. No statistically significant difference of the serum miR-141 levels between the patients with BPH and healthy individuals was observed (P>0.05).The serum miR-141 level was also found to be related to Gleason score, clinical stage and bone me-tastasis status of the patients with PCa (P<0.05), and the patients with higher Gleason scores had higher serum miR-141 levels.No relationship was detected between miRNA-141 level and the patient’ s age, biochemistry recurrence and serum prostate-specific antigen level (P>0.05 for all comparisons).CONCLUSION: Circulating miR-141 could serve as a non-invasive biomarker for prostate cancer diagnosis, staging and prognosis prediction.
